Immunotherapy markers in gynecologic cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how well immunotherapy works for advanced endometrial and cervical cancer by checking certain markers in your blood and tumor. It aims to find out which patients benefit most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 18 years or older.
- You have advanced, metastatic, or recurrent endometrial or cervical cancer.
- Your cancer type has been confirmed as suitable for immunotherapy.
- You have received at least one dose of immunotherapy.
- You are willing to sign a consent form or equivalent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) for patients with a specific type of endometrial cancer that has a high number of gene mutations (called dMMR or MSI-H). The goal is to shrink or eliminate the tumor so surgery may not be needed.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This study looks for new markers in the blood or tumor that could predict how well immunotherapies work for advanced digestive and gynecological cancers. It includes people getting immunotherapy, chemotherapy, or targeted therapy, and also those with certain liver or abdominal metastases that can be surgically removed after chemo.
This Phase 1/2 trial tests an immune-based treatment for advanced (Stage III–IV) GI cancer. You may be able to join only if your tumor shows certain “marker” proteins on special lab staining, and your blood and organ tests meet study limits.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.